Connect with us

Hi, what are you looking for?

Tuesday, May 24, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Tetra Bio-Pharma to receive $4.5M loan from Quebec government

The funds will go toward developing a treatment for acute respiratory distress syndrome, which can result from Covid-19

Tetra Bio-Pharma to receive $4.5M loan from Quebec government - acute respiratory distress syndrome
An X-ray of a patient with acute respiratory distress syndrome. Image by Samir via Wikimedia Commons

Canadian cannabinoid therapeutics developer Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) says it’s been approved for a sizable loan from the Quebec government.

On Wednesday, the company said the $4.5-million participative loan will come from the ministère de l’Économie et de l’Innovation under the biomed propulsion program.

According to Tetra, the funding will support development of ARDS-003 for acute respiratory distress syndrome (ARDS), whether caused by Covid or not. The formulation will also be tested for its treatment of sepsis, the body’s extreme response to an infection.

The transaction is conditional to shareholder approval, which will be decided at a general meeting in May, as it would involve moving the firm’s head office to Quebec from Ontario. More than 60 per cent of Tetra’s staff are already located in Quebec.

Read more: Tetra Bio-Pharma partners with Avicanna to bring cannabinoid medical products to LATAM

The support for Tetra will lead to the development of medication to treat ARDS, such as in severe cases of Covid-19, Economic Minister Pierre Fitzgibbon said in a statement.

“Our government will always be there to support potentially life-changing initiatives for the population, especially when they contribute to the vitality of the Quebec life-sciences sector and Quebec’s reputation in the field of biotechnology.”

Tetra CCO Steeve Néron says his company has been the subject of several diligent reviews by the province’s economic ministry and Investissement Québec, which validates the firm’s scientific, financial and commercial approach.

“In addition, the MEI/IQ adheres to the strategic vision of the team of scientists and managers behind the development of our products. I know that investors have been waiting for this announcement for a long time and I am delighted that it has finally arrived.”


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Nick Laba on Twitter

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can


As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices


Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance


While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe